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170Outcomes with arteriovenous ﬁstulas in a pediatric
population
Sarah M. Wartman, MD, David Rosen, MD, Karen Woo, MD, Wayne S. Gradman, MD,
Fred A. Weaver, MD, and Vincent Rowe, MD, Los Angeles, Calif
Objective: Kidney Disease Outcome Quality Initiative guidelines recommend permanent access in dialysis patients aged
0 to 19 years who weigh >20 kg and are unlikely to receive a transplant within 1 year. Unfortunately, >80% of these
patients currently receive dialysis through a permanent catheter and are exposed to the associated risks and shortcomings.
With a clear imperative to increase the incident use of permanent access in pediatric patients, our objective was to examine
the long-term outcomes of pediatric arteriovenous ﬁstulas (AVFs).
Methods: A retrospective review was performed of all AVFs created in a hemodialysis (HD) population aged 0 to 19 years
at a single institution from 1999 to 2012. Data abstracted included age, weight, etiology of renal failure, time on dialysis,
central venous catheter history, and transplantation history. Data were analyzed to determine the inﬂuence of these
variables on primary and secondary patency.
Results: During the study period, 101 AVFs were performed in 93 patients, of whom 65 patients (70%) were male. Mean
patient age was 14 years (range, 3-19 years), and mean weight was 51 kg (range, 12-131 kg). At the time of AVF creation,
66 patients (82%) were already receiving HD, with a mean length of HD dependence of 18 months. At the time of
surgery, 78% of patients had a previous central venous catheter, and 24% had two or more catheters. Procedures per-
formed included 43 radiocephalic ﬁstulas, 29 brachiocephalic ﬁstulas, 20 basilic vein transpositions, and 9 femoral vein
transpositions. Mean follow-up was 2.5 years. The 2-year and 4-year primary and secondary patency rates were 83% and
92%, and 65% and 83%, respectively. Increasing age was correlated with improved primary patency (P[ .02) but had no
effect on secondary patency. Weight, etiology, catheter location, and catheter history were not signiﬁcantly associated
with primary or secondary patency. During the postoperative period, 68 patients (75%) received a renal transplant, with a
mean time to transplant of 556 days.
Conclusions: AVFs demonstrate excellent long-term patency with minimal complications in pediatric HD patients,
regardless of weight. Concerted efforts should be made to improve the incident use of AVFs in all pediatric patients with
end-stage renal disease. (J Vasc Surg 2014;60:170-5.)The National Vascular Access Improvement Initiative
(NVAII), now known as the Fistula First Breakthrough
Initiative (FFBI), was established in 2003 to improve rates
of arteriovenous ﬁstula (AVF) use for hemodialysis (HD) in
prevalent patients. The goal set by the National Kidney
Foundation’s (NKF) Kidney Disease Outcome Quality
Initiative (K-DOQI) practice guidelines1 of 40% AVF use
was met in August 2005.
In the pediatric population, K-DOQI guidelines re-
commend placement of permanent access in dialysis
patients aged 0 to 19 years who weigh >20 kg and are un-
likely to receive a transplant #1 year. Even though most
pediatric HD patients meet the weight and timing criteria
for placement of permanent access upon initiation of
HD, HD is initiated through a central venous catheterthe Division of Vascular Surgery and Endovascular Therapy, Keck
edical Center, University of Southern California.
or conﬂict of interest: none.
ented at the Twenty-eighth Annual Meeting of the Western Vascular
ciety, Jasper, Alberta, Canada, September 21-24, 2013.
rint requests: Sarah M. Wartman, MD, 1520 San Pablo St, Ste 4300,
s Angeles, CA 90033 (e-mail: sarah.wartman@med.usc.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2014.01.050(CVC) in >90% and through a permanent catheter in
>80%.2 Owing to the success of the FFBI in the adult
HD population, the International Pediatric Fistula First
Initiative (IPFFI) was developed in 2005 to speciﬁcally
address HD access in children and adolescents.3
The feasibility of AVF creation in pediatric patients has
long been documented, but few studies have evaluated
long-term outcomes in large study populations.4-11 The
aim of this study was to examine factors that inﬂuence
the long-term patency and durability of pediatric AVFs in
a large cohort of pediatric patients.METHODS
The Children’s Hospital Los Angeles Committee on
Clinical Investigations approved this study. A retrospective
review was performed of all AVFs created in a HD popula-
tion aged 0 to 19 years at Children’s Hospital Los Angeles
from 1999 to 2012. Data abstracted included age, weight,
sex, etiology of renal failure, time on dialysis, CVC history,
and transplantation history. Etiology of renal failure was
identiﬁed for each patient and then divided into one of
ﬁve general categories: structural, glomerulonephritis,
nephrotic syndrome, metabolic, and other.
The creation of each ﬁstula was performed by one of
two surgeons, and the type of access created was
surgeon-dependent. Vein mapping was performed on all
Table I. Vascular access
Vascular access No. (%) (N ¼ 101)
Previous AVF 10 (10)
Previous CVCa 76 (78)
$2 CVCs 23 (24)
Previous subclavian CVC 33 (42)
$2 subclavian CVCs 13 (13)
CVC on same side as AVF
Subclavian 19 (19)
At time of operation 22 (30)
AVF, Arteriovenous ﬁstula; CVC, central venous catheter.
aTunneled CVC.
Fig 1. Primary patency of pediatric vascular accesses is shown. The
error bars show the standard error.
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vein size, and in general, the minimum size cutoff was
2.0 mm for forearm veins and 2.5 mm for upper arm veins.
Owing to the intense vasospastic response of pediatric ves-
sels, repeat intraoperative vein imaging was routinely per-
formed once the patient was placed under anesthesia.
All AVFs were performed with a standard end-to-side
anastomosis with a continuous running monoﬁlament su-
ture. To decrease the vasospastic response from arterial
clamping and vessel dissection, tourniquet occlusion was
used for inﬂow control in selected cases. Loupe magniﬁca-
tion was used in all surgical cases. An operating microscope
was used by one of the two surgeons on a case-by-case basis
as determined by artery size.
For patients with evidence of upper body central
venous stenosis or other anatomic barriers precluding up-
per extremity AVF, femoral vein transposition (FVT) was
performed.12 All basilic vein transpositions (BVTs) and
FVTs were performed in one stage.
Patients were seen routinely at 2 and 6 weeks postop-
eratively for an initial wound check and clearance for use
of the ﬁstula. Patients with dialysis catheters were seen
again after$2 weeks of consecutive HD through the newly
created AVF for catheter removal. Additional follow-up
with the surgeon was scheduled as needed for patients
with any ﬁstula-related complications, including aneu-
rysmal changes, thrombosis, access site infections, and steal
syndrome. Nephrology and HD records were used to
conﬁrm patency in patients who no longer required surgi-
cal follow-up.
Primary outcome measures were 2-year and 4-year pri-
mary and secondary patency. Primary patency was deﬁned
as the time from AVF creation until any intervention per-
formed to maintain patency or abandonment of the ﬁstula
for any reason without intervention. Secondary patency
was deﬁned as the patency of the AVF from creation to
abandonment for any reason, including the interval before
and after any interventions to re-establish patency in
thrombosed access.13
Statistical analysis was performed using SAS 9.2 soft-
ware (SAS Institute Inc, Cary, NC). Summary results are
reported as mean 6 standard deviation for continuous vari-
ables and as frequency (percent) for categoric variables.
Data were analyzed to determine the inﬂuence of demo-
graphic and perioperative variables on primary and second-
ary patency using Cox proportional hazards models.
Procedure patency rates were calculated by the life-table
method, as outlined by the Committee on Reporting Stan-
dards for Arterio-Venous Accesses of the Society for
Vascular Surgery and the American Association for
Vascular Surgery. A value of P < .05 was considered
signiﬁcant.
RESULTS
During the study period, 101 AVFs were performed in
93 patients, of whom 65 (70%) were male. Mean age was
14 years (range, 3-19 years), and mean weight was 51 kg
(range, 12-131 kg). Etiology of renal failure was secondaryto obstructive pathology in 21 patients, glomerulonephritis
in 40, metabolic diseases in 3, nephrotic syndrome in 9,
and was medication induced, iatrogenic, or unknown in
the remaining 30.
At the time of AVF creation, 66 patients (82%) were
receiving HD through a permanent CVC, with a mean
length of HD dependence of 18 months. Seventy-eight
percent of patients had a history of at least one CVC cath-
eter at any site, and 42% had at least one previous subcla-
vian catheter. In addition, 24% had two or more
catheters, and 17% had two or more subclavian catheters
(Table I). Ten patients (10%) had a previous thrombosed
AVF. The procedures performed were 43 radiocephalic ﬁs-
tulas, 29 brachiocephalic ﬁstulas, 20 BVT, and 9 FVTs.
Mean follow-up was 2.5 years.
Primary patency was 83% at 2 years and 65% at 4 years
(Fig 1). Secondary patency was 92% at 2 years and 83% at
4 years (Fig 2). Increasing age was correlated with
improved primary patency (hazard ratio, 0.88; P ¼ .02)
but had no effect on secondary patency when evaluated
as a continuous variable. There was no speciﬁc age cutoff
at which primary patency was superior when divided into
quartiles and no difference in patency based on absolute
weight as a continuous variable or when grouped as
>20 kg or <20 kg. Etiology of renal failure, sex, catheter
location, and catheter history were not signiﬁcantly associ-
ated with primary or secondary patency. Only a small
Fig 2. Secondary patency of pediatric vascular accesses is shown.
The error bars show the standard error.
Table II. Predictors of arteriovenous ﬁstula (AVF)
patency
Parameter
Primary patency
P
Secondary patency
P
Age .02 .27
Sex .66 .22
Weight .23 .52
Etiology .37 .93
Predialysis .85 .77
CVC same side at operationa .23 .53
History of
CVC same sideb .79 .25
Subclavian CVC same
sidec
.29 .83
CVC, Central venous catheter.
aTunneled CVC on the same side as the ﬁstula at the time of the operation.
bCVC on the same side as the ﬁstula.
cSubclavian CVC on the same side as the ﬁstula.
JOURNAL OF VASCULAR SURGERY
172 Wartman et al July 2014percentage of patients were predialysis, and this did not
affect patency (Table II).
Location of AVF did not signiﬁcantly affect primary
(P ¼ .73) or secondary patency (P ¼ .71). Primary patency
at 2 years was 81% for radiocephalic AVF, 89% for brachio-
cephalic AVF, and 77% for BVT. Primary patency for FVT
was not valid at 2 years using the life-table method owing
to the small sample size, but seven of nine maintained pri-
mary patency at 2 years. The 2-year secondary patency was
93% for radiocephalic AVF, 89% for brachiocephalic AVF,
89% for BVT, and 100% for FVT.
Functional maturation was never achieved in ﬁve ﬁs-
tulas. Thrombosis complicated 11 AVFs, ﬁve of which
were abandoned without intervention. Open surgical revi-
sion was attempted on six, with three remaining patent af-
ter surgical intervention. Seven of the 11 of thrombosed
AVF were radiocephalic, and the three that were success-
fully revised were radiocephalic. Timing was 0 to
374 days for thrombosis, with four occurring #30 days
of surgery.
During the study period, 14 patients (14%) required
revision. As previously noted, six of those patients had
thrombosis. Two required superﬁcialization due to depthof vein, and one required branch ligation. An access site
infection developed in two patients secondary to the “but-
ton-hole” cannulation technique predominantly used in
the pediatric population. One of the infected ﬁstulas was
successfully revised, but one ﬁstula ultimately required
ligation. Symptomatic steal syndrome occurred in three
patients, two BVTs and one FVT; however, no tissue
loss developed. All three patients underwent surgical
revision with distal revascularization interval ligation or
ﬁstula reduction procedures, with improvement in their
symptoms.
Sixty-eight patients (75%) received a renal transplant at
any point during the postoperative period, with a mean
time to transplant of 556 days (1.5 years).
DISCUSSION
With the success of the FFBI in late 2005, and the
revised NKF K-DOQI goal of >65% percent AVF for
HD, the Centers for Medicare & Medicaid Services
(CMS) set a national goal of 66% for prevalent autogenous
ﬁstula HD access in adults.14 Although this goal has yet to
be met on a national level, various states and regions have
successfully reached these numbers. Unfortunately, the
incident creation of AVFs in the pediatric population
does not quite mirror the general adult population.
Data from the North American Pediatric Renal Trials
and Collaborative Studies 2011 Annual Report indicates
that <20% of pediatric patients receive HD through ﬁstulas
or grafts. In fact, initiation of dialysis through a CVC has
increased from 70% to >90% since 2007, even though
greater than two-thirds of children initiating dialysis meet
the established criteria for ﬁstula placement.2 The unex-
plained high prevalence of HD through a CVC in the pe-
diatric population is particularly concerning given that high
rates of stenosis have been reported with long-term CVC
use. Of additional concern in the pediatric HD population
is the alarming rate of subclavian vein catheters. In the
2011 report by the North American Pediatric Renal Trials
and Collaborative Studies, 51% of CVCs were located in
the subclavian vein. Most of the patients in our study had
a history of at least one CVC at any site, and almost half
had at least one previous subclavian catheter. In addition,
nearly 20% had two or more subclavian catheters or a sub-
clavian catheter on the same side as their ﬁstula.
Catheter history and location did not affect patency in
our study, which is surprising given that numerous studies
in adults clearly detail the negative effects of CVCs on cen-
tral veins and the potential effects on patency of ipsilateral
AVFs.15-18 In one study evaluating 233 patients who un-
derwent creation of an AVF after previous HD through a
CVC, 69 had ipsilateral catheters and 164 had contralateral
catheters. In this study, multivariate analysis showed the
only factor that signiﬁcantly affected cumulative AVF sur-
vival was a previous ipsilateral catheter. Although our study
documented that previous CVCs had no effect on ﬁstula
patency, we did not document the presence or absence of
central vein stenosis in our study population before ﬁstula
creation. It is possible that central veins in pediatric patients
JOURNAL OF VASCULAR SURGERY
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or that these patients have a more robust compensatory
system to accommodate the arterialized venous ﬂow of
an AVF with an ipsilateral central vein occlusion or stenosis.
Unfortunately, without preoperative imaging on each pa-
tient with a CVC history, the explanation for our ﬁnding
remains theoretical.
Numerous authors have documented success in crea-
tion of pediatric AVFs, with rates of failure before func-
tional maturation as low as 5% and secondary patency
rates as high as 70% to 100%; however, fewer studies exist
that evaluate long-term outcomes in the pediatric popula-
tion.4,7,8,19,20 Bagolan et al4 evaluated 112 ﬁstulas in 90
patients with a cumulative 4-year patency rate of 63%.
Our study compared favorably at similar follow-up inter-
vals. Compared with contemporary outcomes in adult
AVFs that report 2-year primary and secondary patency
rates of 40% to 69% and 62% to 75%, respectively, pediatric
AVF patency is excellent.21 When analyzed by ﬁstula loca-
tion, no difference in patency was demonstrated.
One study looking at 42 AVF compared two-stage
BVT with all other types and found improved patency at
1 year for two-stage BVT at 91% vs 47% for other type.8
Their study did not, however, compare ﬁstula by location
and included single-stage BVT in the “other” group.
Despite most thrombosis occurring in radiocephalic ﬁstulas
in our study, the overall patency of the ﬁstula was not
determined by location. We therefore advocate adherence
of general ﬁstula guidelines recommending initial place-
ment of permanent access in the distal portion of the
extremity, even in this younger and smaller patient
population.
Our study found increasing age was correlated with
improved primary patency, but there was no exact age cut-
off at which a beneﬁt could be seen. We also could not
demonstrate a correlation between weight and primary or
secondary patency. Similar to our results, in an evaluation
of 24 AVF created in pediatric patients, Sheth et al9 could
not validate a correlation of patency with patient age or
weight at access creation. In a different study, Bagolan
et al4 were able to demonstrate a difference in patency
based on weight in their evaluation of 90 pediatric patients.
Their 4-year patency rate was 70% in patients weighing
>15 kg and 57% in patients weighing <15 kg.4 The exten-
sion of their weight criteria may account for the effect
on patency seen in their study, in which 18% of patients
weighed <15 kg compared with only 5% weighing
#20 kg in our study.
It is possible that the high prevalence of HD through a
CVC seen in our patient population, in previous studies,
and in the general pediatric population is due to a reluc-
tance to place ﬁstulas in patients with smaller ves-
sels.4,9,19,22 Although the precise vessel size was not
consistently recorded in our study, surrogate markers of
the patient’s weight and age allow inference about the
size of the patient. Perhaps in the pediatric population,
any analysis using weight and age as variables should also
determine the deviation of each child from the normalgrowth curve. This additional information may provide
insight into the expected vessel size and growth potential
vs the actual vessel size and be more valuable in deter-
mining criteria for ﬁstula creation.
Most of our patients received a renal transplant during
the study period. Although shorter time to transplant is a
consideration in pediatric patients, 60% of pediatric HD pa-
tients will not receive a transplant within the ﬁrst year of
HD initiation.23,24 In addition, should patients outlive
their transplants, the long-term effects of multiple previous
catheters may affect the options for creation of AVF after
transplant. In a survey of 25 pediatric HD patients at our
study institution, fear of needles and cosmetic concerns
of permanent AV accesses in the extremity were frequently
cited as major deterrents to ﬁstula placement (unpublished
data). Despite the initial reluctance, we strongly advocate
placement of AVFs for permanent HD access. This recom-
mendation is especially true in patients in their late teen-
aged years, where after age 18 years, transition to an
adult renal transplant waiting list is accompanied by
extended time on HD.
CONCLUSIONS
AVFs demonstrate excellent long-term patency, with
minimal complications, in pediatric HD patients regardless
of weight. Concerted efforts should be made to improve
incident use of AVFs in all pediatric end-stage renal disease
patients.
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colleagues at the University of Southern California have presented
a 13-year experience of creating 101 arteriovenous ﬁstulas in 93
patients. The procedures were performed by only two surgeons.
The bulk of the procedures were radiocephalic ﬁstulas, but there
were a signiﬁcant number of brachiocephalic and basilic transposi-
tion ﬁstulas, and a small number of femoral transpositions. Eight-
two percent of the patients were already on hemodialysis at the
time of ﬁstula creation, and 78% had a prior central venous cath-
eter. Overall, their results are excellent and consistent with other
publications, with primary patency of 83% and secondary patency
of 92%. The authors found that gender, weight, etiology of renal
failure, previous central venous catheter and their location, and
whether the patient was already on dialysis had no impact on
patency. Only age inﬂuenced ﬁstula patency.
Strategies for management of renal failure are a little different
in the pediatric population, with preemptive transplant being the
ﬁrst preference and peritoneal dialysis also being more prevalent
than in adults. Nevertheless, >50% of pediatric patients requiring
renal replacement therapy end up on hemodialysis. Despite Kidney
Disease Outcomes Quality Initiative guidelines recommending
arteriovenous ﬁstula (AVF) as the preferred hemodialysis access
and literature showing short- and long-term success rates that
are even better than in adults, the majority of pediatric patients
receiving hemodialysis are dialyzing via central catheters. Review
of the manuscript does raise several questions:
The most important factor in dialysis access is usability, not ﬁs-
tula patency, yet you only report on the latter. Can you tell us how
many of these ﬁstulas were actually used and for how long?
Can you explain why you believe that age impacted ﬁstula
patency but not weight? It would seem that the two variables
should track each other to some extent.
There is no apparent analysis of outcomes depending on ﬁstula
type. I know the numbers are small, but did you evaluate whether
your outcomes were different for different types of ﬁstulas?
Can you tell us what proportion of your overall pediatric dial-
ysis population this report represents? What percentage of patientsat your institution are dialyzing via catheters and are on peritoneal
dialysis?
Finally, there was little information in the manuscript
regarding the decision-making process that was used for ﬁstula
type selection and technical details of you procedures that might
help others achieve these type of excellent results. Can you provide
us any information regarding those issues? I enjoyed the presenta-
tion and complement the authors on their results.
Dr Sarah M. Wartman. We would like to thank Dr Hye for
his thoughtful comments and questions. Indeed, pediatric end-
stage renal disease patients have certain considerations that are
different from the adult population. As Dr Hye has mentioned
in his discussion of our paper, there is a signiﬁcantly higher per-
centage of pediatric patients dialyzing through catheters than
adult hemodialysis patients. The question of why remains to be
answered and is outside the scope of this study. It is, nevertheless,
a source of concern when studying pediatric hemodialysis, and we
have an ongoing project that is designed evaluate the decision-
making process of pediatric hemodialysis patients and their par-
ents when choosing a catheter vs a ﬁstula. Because our current
paper speciﬁcally addresses outcomes with AVF placement, we
did not expand our data collection to include all hemodialysis
and peritoneal dialysis patients at our institution and, therefore,
did not capture the percentage of patients that dialyzed through
a catheter or with peritoneal dialysis.
In general, all ﬁstulas were performed with a standard end-to-
side anastomosis with a continuous running monoﬁlament suture,
with tourniquet occlusion in selected cases. Loupe magniﬁcation
was used for all cases and an operating microscope was used by
one of the two surgeons on a case-by-case basis. Femoral vein
transposition technique is described in Rutherford’s Vascular Sur-
gery and includes references to a technique described and reported
by Dr Wayne Gradman. All basilic and femoral vein transpositions
were performed in one stage. In our study, ﬁstula patency was not
affected by the location of the ﬁstula. Although the subset analysis
was limited by small numbers in some groups, it did not appear to
change the outcomes for patency.
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patency where a ﬁstula was considered patent only while being used
by the patient. For a large cohort of patients in this study, the end
of ﬁstula patency was their date of transplant, regardless of the fact
that their AVF could still be accessed and was still technically pat-
ent. In fact, there were some patients that actually went back to us-
ing their original AVF after transplant failure, but due to the
inability to follow all patients for this possible outcome, we didnot include this time period our analysis. With this in mind, our
patency data is an accurate reﬂectiondif not an underestimationd
of the usability of our patients’ arteriovenous ﬁstulas.
Finally, the reason for the signiﬁcant impact of age, but not
weight, on ﬁstula patency was perplexing to us. It is possible that
the size of vessel is not reﬂected as much by the patient’s weight
as it is by their age. In addition, only 5% of our patients weighed
<20 kg, which may have impacted our analysis.
